Weight Watchers account plan
Personalized weight management support
At a glance
Weight Watchers runs subscription weight-management programs and a U.S. GLP-1 telehealth clinic, with 2.3 million subscribers and about 3,500 employees.
WW International, Inc. (Weight Watchers), headquartered in New York, sells subscription weight-management programs combining community, nutrition, behavioral science, digital tools and coaching, and in the U.S. gives access to clinicians who can prescribe GLP-1 medications. It offers three tiers: Core and Core+ (Behavioral) and Med+ (Clinical), directly and through Weight Watchers for Business to employers and health plans. The company emerged from Chapter 11 on June 24, 2025; fiscal 2025 revenue was $347.1 million (June 25 to December 31) plus $363.6 million (December 29, 2024 to June 24, 2025). It had about 3,500 employees in nine countries at December 31, 2025, and 2.3 million subscribers at September 30, 2026. Stephen J. Bye became President and CEO on October 1, 2026.
Business units
Behavioral (Core and Core+)
about 83% of fiscal 2025 revenue (computed); $592.6 million combined Behavioral Subscription RevenueDigital subscriptions to the Points Program, app and community, with Core+ adding unlimited coaching, workshops and GLP-1, Diabetes and Menopause programs, sold worldwide. Q3 2026 Behavioral revenue fell 21.5% to $113.9 million and subscribers fell 25.9%, but Core+ reached 546 thousand subscribers, up 16%.
Clinical (Med+, Weight Watchers Clinic)
about 16% of fiscal 2025 revenue (computed); $112.8 million combined Clinical Subscription RevenueU.S.-only telehealth subscription in which clinicians prescribe medications including oral and injectable GLP-1s and hormone replacement therapy, with insurance coordination. Q3 2026 Clinical revenue rose 47.6% to $38.0 million, or 25% of revenue, with 174.3 thousand subscribers (+40.4%).
Other Revenue
about 0.7% of fiscal 2025 revenue (computed)Licensing of trademarks for food and other weight-related products, franchise fees, royalties and publishing; Q3 2026 Other Revenue was $941 thousand.
Weight Watchers for Business
A channel selling Behavioral and Clinical offerings to employers, payers and health plans, including the RxFlexFund that lets employers subsidize GLP-1 costs; it is still a small percentage of revenue, with a UnitedHealth partnership expanding.
Strategic priorities
- Grow the higher-value tiers
- Core+ and Med+ now generate roughly half of revenue; Clinical is expected at about 25% of full-year 2026 revenue, against about 16% in 2025.
- Lower churn and longer lifetime value
- CEO Stephen Bye wants to remove friction points in every customer journey, lower churn and keep investing in the app and emerging technology.
- Ongoing guidance in a commoditized GLP-1 market
- Bye sees GLP-1 access becoming commoditized and a gap in ongoing nutritional and behavioral support, which Core, Core+ and Med+ are designed to fill.
- Clinical intake and pricing clarity
- COO Jon Volkmann plans to match members to the right pathway using medical history, goals and insurance profile, with earlier cost transparency for medication.
- Diversified marketing and partnerships
- After Q1 awareness gains did not carry through the year, the company is building a more diversified marketing approach and exploring partnerships beyond Google Health, Sam's Club and LillyDirect.
- Return to profitable growth in 2027
- Bye aims to return the business to sustainable, profitable growth in 2027 with operating and fiscal discipline.
Latest results
In Q3 2026 (quarter ended September 30, 2026) revenue was $152.9 million, down 11.2%, as Behavioral Subscription Revenue fell 21.5% and Clinical rose 47.6%. End of Period subscribers fell 23.1% to 2,296.0 thousand, while monthly revenue per average subscriber rose 14.3% to $21.17. Operating income was $36.5 million and net income $15.1 million against a $57.5 million loss a year earlier; Adjusted EBITDA rose 21% to $51.7 million. Full-year 2026 guidance was narrowed to revenue of $625 million to $630 million and Adjusted EBITDA of $110 million to $115 million.
Investments and deals
- App re-platforming and AI features
- The app was relaunched in January 2026 on rebuilt infrastructure with an AI Body Scanner, AI-powered Food Tracker and Recipe Analyzer; capitalized software and website development was $18,899 thousand over nine months of 2026.
- Debt reduction
- Debt was cut from approximately $1.6 billion to $423.6 million; in May 2026 the company retired $14.6 million of principal at 68.5% of par and paid a $26.8 million excess-cash sweep in June.
- Peoplehood asset acquisition
- On August 6, 2025 the company acquired assets of Peoplehood, a wellness support platform, for $1.0 million in cash plus $1.0 million deferred.
- Brand modernization
- The company is modernizing the brand into "a bolder, more contemporary identity that is credible in medical solutions"; peak-season marketing raised Med+ awareness by 8 points to 30%.
Challenges and risks
- Shrinking Behavioral base
- Behavioral subscribers fell 25.9% in Q3 2026, and Core faces "multiyear ongoing secular headwinds" as consumers focus on medications.
- GLP-1 competition
- Telehealth providers, pharma, pharmacies, free apps and generative-AI tools compete for members, and medication access is becoming commoditized.
- Clinical subscriber volatility
- Clinical subscribers fell from 197.3 thousand at the end of June to 174.3 thousand at September 30, 2026 after compounded semaglutide plans came up for renewal and Q3 marketing was lower.
- Costly debt and impairment risk
- The term loan carries a weighted average rate of about 10.48%, and the Behavioral reporting unit and trade name were identified as at risk of impairment.
- Leadership transition
- Tara Comonte resigned in March 2026 and Stephen J. Bye started on October 1, 2026; the 10-Q warns the transition could slow "progress on key strategic initiatives".
What leadership says
“I'll be very clear. I believe this business is not living up to its potential.”
“access to GLP-1 medication is becoming increasingly commoditized and new options are coming”
“remained focused on strengthening our two higher-value product offerings and proactively calibrating our spend across our portfolio”
“GLP-1 medications represent a permanent structural shift in how the world understands weight, obesity, and metabolic health.”
Where a supplier can help
- Retention and lifecycle marketing
- Lowering churn and extending lifetime value is a stated CEO priority; customer engagement, personalization and subscription analytics vendors fit directly.
- Diversified acquisition channels
- Management is building a more diversified marketing approach and exploring new partnerships; performance marketing, affiliate and retail-partner platforms address this priority.
- Clinical operations tooling
- Better clinical intake, prior authorization navigation and earlier cost transparency are COO priorities; telehealth workflow, eligibility and benefits verification tools can support them.
- Employer and health plan channel
- Weight Watchers for Business and the RxFlexFund sell to employers and payers; benefits platforms and brokers can help scale this still-small channel.
- Workflow automation
- Adjusted gross margin gains came from workflow automation; automation and AI vendors can help hold margins as the mix shifts to labor-heavier Clinical.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Weight Watchers?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- WW International, Inc. Annual Report on Form 10-K, fiscal year ended December 31, 2025
- WW International (Weight Watchers) sells subscription weight-management programs in three tiers: Core (digital app), Core+ (adds unlimited coaching and in-person/virtual workshops) and Med+ (U.S.-only telehealth access to clinicians who can prescribe GLP-1s and other medications). It reports one operating segment, with Behavioral and Clinical business lines.
- The company filed a prepackaged Chapter 11 on May 6, 2025 and emerged on June 24, 2025: about $1,116.0 million of prepetition credit facilities and $500.0 million of notes were discharged and replaced by a $465.0 million term loan maturing June 24, 2030. The new stock was relisted on Nasdaq on July 3, 2025.
- Fiscal 2025 revenue was $347.1 million (Successor, June 25 to Dec 31) plus $363.6 million (Predecessor), against $785.9 million in fiscal 2024. Combined Subscription Revenue fell 9.2% to $705.4 million.
- Behavioral Subscription Revenue fell 15.2% to $592.6 million, and Behavioral subscribers fell 18.9% to about 2.6 million. Clinical Subscription Revenue grew 44.7% to $112.8 million, and Clinical subscribers grew 41.9% to about 130.2 thousand.
- Gross margin was 71.2% in the Successor period, against 67.8% in fiscal 2024. Adjusted EBITDA was $65.3 million (Successor) and $87.7 million (Predecessor), against $146.5 million in fiscal 2024.
- Unrestricted cash was $160.3 million at December 31, 2025. The term loan carried a weighted average interest rate of about 10.91%.
- Leadership was largely new: Tara Comonte (CEO), Felicia DellaFortuna (CFO), CTO Hélène Causse (October 2025) and CMO Nina George (November 2025). Eugene I. Davis, a restructuring specialist, has chaired the board since June 2025, and former Lilly Diabetes and Obesity president Michael Mason joined the board.
- Strategy is to redefine weight management "for the GLP-1 era": a full re-platforming of the app, GLP-1 Success and Menopause programs, a modernized brand, and Weight Watchers for Business (employers, payers, health plans, with RxFlexFund).
- Main risks are GLP-1-driven competition (telehealth, pharma, compounded drugs, apps), shrinking Behavioral subscribers, healthcare regulation (corporate practice of medicine, fraud and abuse laws), impairment, and reliance on marketing during seasonal Q1 recruitment.
- WW International, Inc. Quarterly Report on Form 10-Q, quarter ended September 30, 2026
- Q3 2026 (quarter to September 30, 2026) revenue was $152.9 million, down 11.2% from $172.1 million. Behavioral Subscription Revenue fell 21.5% to $113.9 million, while Clinical Subscription Revenue rose 47.6% to $38.0 million.
- End of Period subscribers were 2,296.0 thousand, down 23.1%: Behavioral 2,121.7 thousand (-25.9%) and Clinical 174.3 thousand (+40.4%).
- Monthly revenue per average subscriber rose 14.3% to $21.17. Behavioral was $17.21 (+5.0%) and Clinical $68.25 (-0.4%).
- Gross margin was 71.1% (72.1% a year earlier), pressured by the mix shift to Clinical. Operating income was $36.5 million and net income $15.1 million, against a $57.5 million loss a year earlier.
- Marketing fell 31.6% to $33.1 million. SG&A fell 43.7% to $33.8 million on lower D&A, lower transaction costs and expense discipline.
- Nine months: revenue $483.5 million, net loss $22.8 million, operating cash flow $23.0 million and capitalized software spend $18.9 million.
- Debt: a May 2026 buyback of $14.6 million of the term loan at 68.5% of par plus a June $26.8 million cash sweep cut principal to $423.6 million. Cash was $126.4 million.
- CEO transition: Tara Comonte resigned in March 2026. CFO Felicia DellaFortuna and COO Jonathan Volkmann ran an Interim Office of the Chief Executive from April 3, and Stephen J. Bye became CEO effective October 1, 2026.
- The Behavioral reporting unit and the trade name were flagged at risk of impairment, with fair value less than 10% above carrying value at May 1, 2026.
- Weight Watchers Announces Third Quarter 2026 Results (earnings press release, Form 8-K Exhibit 99.1)
- Q3 2026 results (November 5, 2026): revenue of $152.9 million, down 11% year over year. Clinical Subscription Revenue of $38.0 million was up 48% and made up 25% of revenue, against 15% in Q3 2025.
- Core+ (premium Behavioral tier) End of Period Subscribers were 546 thousand, up 16%, the fourth consecutive quarter of sequential growth. Clinical subscribers were 174 thousand (+40%), and total subscribers were 2.3 million.
- ARPU was $21.17, up 14%. Gross margin was 71.1% and Adjusted Gross Margin 74.6%.
- Net income was $15.1 million (9.9% margin), against a $57.5 million loss. Adjusted EBITDA rose 21% to $51.7 million (33.8% margin).
- Cash was $126.4 million, up from $101.5 million at the end of Q2 2026.
- Fiscal 2026 guidance was narrowed: revenue of $625-630 million (previously $620-635 million) and Adjusted EBITDA of $110-115 million (previously $105-115 million).
- New CEO Stephen Bye, who joined October 1, says his focus is "strengthening our member experience, improving our products and applications". CFO Felicia DellaFortuna describes "proactively calibrating our spend across our portfolio".
- WW International Q3 2026 Earnings Call (corrected transcript), Stephen Bye's first call as CEO
- Stephen Bye's first earnings call as CEO (Q3 2026, November 5, 2026), with CFO Felicia DellaFortuna and COO Jon Volkmann.
- Bye's thesis: GLP-1 access "is becoming increasingly commoditized", which opens a gap in "ongoing guidance, including nutritional and behavioral support". He argues the total addressable market is growing, whether or not members get their medication from Weight Watchers.
- He states plainly: "I believe this business is not living up to its potential". His goal is to "return this business to sustainable, profitable growth", which he says the company is well-positioned to achieve in 2027.
- Core+ and Med+ now generate roughly half of revenue. Core+ grew for a fourth straight sequential quarter, which the CFO says has not happened in 20 years. GLP-1 Success Program enrollment in Core+ more than doubled since January.
- Clinical subscribers fell from 197,000 to 174,000 sequentially, as 12-month plans sold during the exit from compounded semaglutide came up for renewal. Clinical is expected to be about 25% of 2026 revenue, against about 16% in 2025.
- Total debt has been cut by more than 70%, from about $1.6 billion to $423.6 million. Operating cash flow was $32.3 million in the quarter. Expected 2026 interest costs are about $45-50 million.
- Partnerships named on the call (Google Health, Sam's Club, LillyDirect) were too early to report on. Medicare's GLP-1 Bridge Program is supported through both Med+ and Core+.
- Priorities: reduce member friction and churn, better clinical intake matching, earlier medication cost transparency, app and product upgrades, and bringing in-person community support into virtual formats.
- WW International Q4 and Full Year 2025 Earnings Call (corrected transcript), Tara Comonte's last call as CEO
- Tara Comonte's last earnings call as CEO (Q4 and full-year 2025, March 16, 2026), with CFO Felicia DellaFortuna and COO Jon Volkmann. She resigned later that month.
- Comonte: GLP-1s are "a permanent structural shift". About 10 million Americans are on them, and McKinsey estimates 25-50 million by 2030. Weight Watchers is moving to "an integrated weight health ecosystem that includes medication access and clinical care", not a "prescription-only telehealth business".
- Turnaround since Chapter 11: legacy debt cut by more than 70%, leadership team rebuilt, brand refreshed, product and pricing reset, and a new app relaunched in January 2026 on a rebuilt code base.
- The January campaign raised Med+ awareness by 8 points to 30%. 35% of new U.S. members were first-time members, rising to 50% in Med+.
- Q4 2025: revenue $163 million (-12%), Clinical revenue +32%, Behavioral -17%, Adjusted EBITDA $18 million (11.1% margin), cash $160 million.
- Q1 2026 expectations: about 200,000 clinical subscribers (roughly 100% growth excluding compounded semaglutide) and about 2.45 million Behavioral subscribers (about -26%).
- 2026 guidance at the time: revenue $620-635 million and Adjusted EBITDA $105-115 million. 40-45% of marketing was front-loaded into Q1. Headwinds include about $50 million from the lower Behavioral base and about $20 million of 2025 compounded-semaglutide revenue.
- B2B is still a small share of revenue. The UnitedHealth partnership is expanding, and RxFlexFund embeds Med+ in employer GLP-1 subsidies. Wegovy pill demand exceeded projections.
Questions about Weight Watchers
What does Weight Watchers do?
Weight Watchers sells subscription weight-management programs (Core and Core+) built on nutrition, behavioral science, coaching and community, and in the U.S. a telehealth membership (Med+) where clinicians can prescribe GLP-1 medications.
What is Weight Watchers' revenue?
Q3 2026 revenue was $152.9 million, and the company guides to $625 million to $630 million for fiscal 2026. Fiscal 2025 revenue was split into $363.6 million before and $347.1 million after its emergence from Chapter 11.
How many employees does Weight Watchers have?
About 3,500 employees in nine countries at December 31, 2025, a majority of them part-time.
Who leads Weight Watchers?
Stephen J. Bye has been President and CEO since October 1, 2026, with Felicia DellaFortuna as CFO and Jonathan Volkmann as COO.
What is Weight Watchers' strategy for the GLP-1 era?
It positions itself as the support system around GLP-1 medications, growing Med+ and Core+, lowering churn, improving the app and returning to profitable growth in 2027.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)